Business Context and Reporting Period
Company: Nuvilex, Inc. (formerly eFoodSafety.com, Inc.)
Filing Type: Form 10-Q (Quarterly Report)
Reporting Period: Three months ended July 31, 2009
Business Overview: Nuvilex is an early-stage company focused on developing and marketing health and wellness products, including nutritional supplements (Cinnergen, Cinnechol), scar reduction cream (Talsyn), and tattoo ink (Infinitink). The company recently shifted strategy from food safety to consumer health products.
Key Financial Metrics
| Metric | Q1 2010 (Ended July 31, 2009) | Q1 2009 (Ended July 31, 2008) |
|---|---|---|
| Revenues | $67,947 | $290,255 |
| Gross Profit | $26,155 | $235,831 |
| Gross Margin | 38.5% | 81.2% |
| Net Loss | $(814,924) | $(498,626) |
| Operating Cash Flow | $(554,723) | $(167,407) |
| Cash and Equivalents (End of Period) | $55,860 | $1,345,593 |
| Total Debt (Current + Long-term) | $2,387,061 | $2,415,085 |
| Working Capital | $(606,999) | $(N/A - Data not explicitly stated for prior period) |
Material Changes vs. Prior Period
- Revenue Decline: Revenues dropped 76.6% year-over-year, primarily due to the termination of a major retail contract for the Cinnergen product and strategic price reductions on Cinnergen and Talsyn products to improve competitiveness.
- Expense Increases:
- R&D: Increased from $9,724 to $244,047 due to development of new products (Last Shot Hangover Remedy, Prevorex, Cyclosurface3).
- Sales & Marketing: Increased from $16,242 to $147,645, driven by the launch of new marketing campaigns.
- General & Administrative: Increased from $138,918 to $362,117, attributed to patent expenses and costs associated with operating the new Freedom-2 facility.
- Non-Operating Items: The company recorded a $55,000 loss on the settlement of a loan receivable from Diamond Ranch Foods, Ltd., where the company accepted a lump sum payment of $35,000 to cancel a $100,000 note.
- Liquidity Deterioration: Cash reserves decreased by approximately $548,000 during the quarter, leaving the company with only $55,860 in cash as of July 31, 2009.
Outlook, Risks, and Management Commentary
Going Concern Warning: Management and independent auditors have expressed substantial doubt about the company's ability to continue as a going concern. The company has an accumulated deficit of over $30 million and a working capital deficit of approximately $607,000. Continued operations depend on securing additional debt or equity financing.
Management Strategy:
- Cost Containment: The company is attempting to reduce overhead, including listing its 22,400 sq. ft. Cherry Hill facility for sale or lease.
- Product Focus: Discontinued low-revenue products (I-Boost Immune Bar) and is focusing on higher-margin products and new launches (Last Shot, Prevorex).
- Capital Needs: The company explicitly states it requires additional funding to finance inventory production and marketing efforts.
Risks and Contingencies:
- Litigation: Former executive Kurt Mussina has sued the company seeking approximately $175,000 in unpaid severance. The company disputes the claim.
- Customer Concentration: 77% of revenue is derived from the Cinnergen product line, with significant reliance on a small number of customers.
- Control Issues: A single shareholder (Berkshire Capital Management) holds all Series E Preferred Stock, controlling approximately 66.6% of voting power.
- Internal Controls: Management concluded that disclosure controls and procedures were not adequately effective as of July 31, 2009.
Investor Verification Checklist
- Cash Runway: Verify the company's ability to operate with only $55,860 in cash against a quarterly burn rate of over $550,000.
- Financing Status: Confirm if the company has secured the "bridge financing" or equity capital mentioned as necessary for survival.
- Real Estate Asset: Investigate the status of the Cherry Hill facility sale/lease, which is estimated at $1.7 million but encumbered by multiple mortgages.
- Legal Exposure: Monitor the outcome of the Mussina lawsuit regarding the $175,000 severance claim.
- Revenue Sustainability: Assess the impact of the terminated Cinnergen contract and whether new product launches can offset the 76% revenue decline.